ESTRO 2023 - Abstract Book

S976

Digital Posters

ESTRO 2023

Conclusion HS VMAT does not compromise target volume coverage in RT of NPC and could potentially reduce long term cognitive decline in NPC patients. We propose its inclusion in RT planning protocols for NPC treatment.

PO-1220 Feasibility and compliance of StrataXRT in treatment of radiation dermatitis in head and neck cancer

G. Mckee 1 , L. Rutten 1 , P. Larsen 2 , A. Leong 2,3

1 Wellington Blood and Cancer Centre, Radiation Therapy, Wellington, New Zealand; 2 University of Otago, Department of Radiation Therapy, Wellington, New Zealand; 3 Bowen Icon Cancer Centre, Radiation Therapy , Wellington, New Zealand Purpose or Objective The aim of this study was to evaluate the feasibility of Strata XRT (SXRT) in the treatment of radiation dermatitis in head and neck cancer (HNC) patients. SXRT tolerability, compliance and usage were assessed alongside clinician, radiation therapist (RT), and patient perspectives on toxicity. Comparison was against a historical control cohort managed using Fatty E cream (FEC). Materials and Methods Patients with a diagnosed HNC, aged 18 years or older and prescribed ≥ 45Gy were eligible for this study. An adjusted version of the Radiation Induced Skin Reaction Assessment Scale (aRISRAS) was developed to capture patient experience and utilisation of SXRT in addition to RT-reported dermatitis and patient-reported impact of skin reaction. RTs were trained in aRISRAS scoring, and assessed for consistency amongst RTs and against clinicians. Dermatitis was scored by clinicians using